Clinical trial
Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma
NCT00327327 · AmpliMed Corporation, Industry · Completed
Key facts
| NCT number | NCT00327327 |
|---|---|
| Title | Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma |
| Official title | A Phase 1 Trial of Amplimexon® (Imexon, Inj.) Plus Gemcitabine in Advanced, Previously Untreated Pancreatic Adenocarcinoma |
| Lead sponsor | AmpliMed Corporation, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Pancreatic Adenocarcinoma |
| Intervention type | Drug |
| Interventions | imexon, gemcitabine |
| Enrollment | 105 |
| Start date | Feb 1, 2004 |
| Primary completion | Oct 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | May 18, 2006 |
| Last update posted | Sep 15, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: